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Background: Long QT syndrome (LQTS) is an autosomal dominant condition predisposing to sudden death
from malignant arrhythmia. Genetic testing identifies many missense single nucleotide variants of uncertain
pathogenicity. Establishing genetic pathogenicity is an essential prerequisite to family cascade screening. Many
laboratories use in silico prediction tools, either alone or in combination, or metaservers, in order to predict
pathogenicity; however, their accuracy in the context of LQTS is unknown. We evaluated the accuracy of five
in silico programs and two metaservers in the analysis of LQTS 1–3 gene variants.
Methods: The in silico tools SIFT, PolyPhen-2, PROVEAN, SNPs&GO and SNAP, either alone or in all possible
combinations, and the metaservers Meta-SNP and PredictSNP, were tested on 312 KCNQ1, KCNH2 and SCN5A
gene variants that have previously been characterised by either in vitro or co-segregation studies as either
“pathogenic” (283) or “benign” (29). The accuracy, sensitivity, specificity and Matthews Correlation Coefficient
(MCC) were calculated to determine the best combination of in silico tools for each LQTS gene, and when all
genes are combined.
Results: The best combination of in silico tools for KCNQ1 is PROVEAN, SNPs&GO and SIFT (accuracy 92.7%, sensitivity
93.1%, specificity 100% and MCC 0.70). The best combination of in silico tools for KCNH2 is SIFT and PROVEAN or
PROVEAN, SNPs&GO and SIFT. Both combinations have the same scores for accuracy (91.1%), sensitivity (91.5%),
specificity (87.5%) and MCC (0.62). In the case of SCN5A, SNAP and PROVEAN provided the best combination
(accuracy 81.4%, sensitivity 86.9%, specificity 50.0%, and MCC 0.32). When all three LQT genes are combined,
SIFT, PROVEAN and SNAP is the combination with the best performance (accuracy 82.7%, sensitivity 83.0%,
specificity 80.0%, and MCC 0.44). Both metaservers performed better than the single in silico tools; however,
they did not perform better than the best performing combination of in silico tools.
Conclusions: The combination of in silico tools with the best performance is gene-dependent. The in silico tools
reported here may have some value in assessing variants in the KCNQ1 and KCNH2 genes, but caution should be
taken when the analysis is applied to SCN5A gene variants.
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Long QT syndrome (LQTS) is a heritable cardiac dis-
order characterised by a prolonged QT-interval detected
on an electrocardiogram (ECG), episodes of syncope,
and the risk of sudden death. The estimated number of
affected people is 1 in 2,500 [1,2], and 13 causative genes
have been identified. The majority of these genes encode
for the cardiac ion channels (potassium, sodium and
calcium). Loss-of-function mutations in the KCNQ1 and
KCNH2 genes (LQT1 and LQT2, respectively) account
for ~65% of all LQTS cases, and gain-of-function muta-
tions in the SCN5A gene (LQT3) account for 10% of all
LQTS cases [3,4]. Genotype-phenotype correlation stud-
ies have established genotype-specific ECG patterns,
arrhythmia triggers and outcomes [5,6]. Genetic diagno-
sis permits better risk stratification, clinical management
and cascade family screening [7].
As genetic testing becomes more widely available, an
increasing number of variants of unknown/uncertain sig-
nificance are being discovered. Before family cascade
screening can be undertaken, it is essential to be confident
of the pathogenicity of the variant. While nonsense and
frameshift mutations, which cause premature termination
of protein production, are usually pathogenic, missense
mutations are very commonly benign. The interpretation
of novel single nucleotide variants (SNVs) is difficult.
SNVs represent ~75% of clinically positive LQTS test re-
sults [8]. Approximately 1 in 25 healthy individuals are
expected to have a rare, benign variant in one of the three
major LQTS genes [9,10]. The best methods to assess
the pathogenicity of novel mutations are to undertake
phenotype-genotype family co-segregation studies, and
functional/biophysical studies in an in vitro system or
animal models. However, many families are too small,
and the latter two methods are expensive and time-
consuming and unavailable to most diagnostic services.
With the growing number of unclassified SNVs, many
diagnostic laboratories use in silico missense mutation
prediction tools to determine whether a novel SNV is
pathogenic in relation to the evolutionary conservation
of specific amino acids, as well as protein structure and
function.
The prediction tools can be broadly divided into three
categories: sequence and evolutionary conservation-based
methods, protein sequence and structure-based methods,
and supervised learning methods (refer to [3,11-13] for
reviews of the different categories). The sequence and evo-
lutionary conservation-based methods assess the patho-
genicity of a mutation based on the conservation of a
particular amino acid across different species [14-16]. Pro-
tein sequence and structure-based methods assess SNVs
based on their location in the protein structure and how
they may impact/disrupt the overall protein [17]. The su-
pervised learning methods are trained on large defineddatasets so that they can “learn” to distinguish pathogenic
mutations from benign variants [15,18,19].
Several studies have investigated the use of multiple in
silico prediction tools to assess the predictive accuracy of
these tools [20-28]. There are also consensus programs
(metservers) that combine the output from several in silico
prediction tools and produce a single consensus outcome,
all of which have been reported to offer improved per-
formance over individual tools [29-31]. However, no study
has investigated the combination(s) of individual in silico
prediction tools with the best performance for LQTS
genes or whether the use of metaservers is better.
The aim of the study described here was to assess the
predictive accuracy of five in silico programs (SIFT,
PolyPhen-2, PROVEAN, SNPs&GO and SNAP), alone
or in combination, and two metaservers (Meta-SNP
and PredictSNP) in evaluating SNVs in the three major
LQTS genes (KCNQ1, KCNH2 and SCN5A). All muta-
tions reported in the Inherited Arrhythmia Database
[32] for these genes were analysed to determine the
combination of the in silico programs with the best per-
formance, and how the combinations compared to the
use of the metaservers.Methods
All LQTS gene SNVs (both deleterious, polymorphisms
and rare SNVs) were collated from the Inherited
Arrhythmia Database (http://www.fsm.it/cardmoc/ last
accessed October 2014), Kapplinger et al. [33], Giudi-
cessi et al. [5] and the LQTS gene LOVD database [34].
Only SNVs that caused missense amino acid changes
were considered for analysis. For this study the SNVs
were divided into two groups: pathogenic and benign.
To be considered for the pathogenic group, SNVs must
either be functionally characterised by in vitro and/or
have undergone co-segregation studies to prove they
are pathogenic. In the case of the benign group, SNVs
must either be functionally characterised by in vitro
studies and/or must have an allele frequency of greater
than 1%. SNVs in the SCN5A gene reported by Kapplinger
et al. [33] were found in either LQTS and/or Brugada syn-
drome patients. All the mutations that were analysed and
their respective results are shown in Additional file 1: Data
tables, and their locations in respect of the different pro-
tein regions (transmembrane domains, pore regions, etc.)
are shown in Additional file 2: Figures S1–S3.
Five in silico missense mutation prediction tools and
two metaservers, listed in Table 1, were used to analyse all
the LQTS genes SNVs and the exact methodology and
algorithms used by each of these have been described pre-
viously according to the references given here: PolyPhen-2
[17], SIFT [14], PROVEAN [16], SNPs&GO [18,35], SNAP
[19], Meta-SNP [30] and PredictSNP [31].
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if a missense mutation is situated in a structurally im-
portant/functional site in the protein using a naïve
Bayesian approach [17]. Therefore, PolyPhen-2 could
belong to the supervised-learning method of in silico
analysis [13]. LQTS SNVs were analysed by accessing
the web-based method PolyPhen-2, using default set-
tings [17]. PolyPhen-2 classified each variant as “Prob-
ably damaging”, “Possibly damaging”, or “Benign”. For
the purposes of this study, SNVs assigned as “Probably
damaging” or “Possibly damaging” were classified as
“damaging” for downstream analysis.SNPs&GO incorporates sequence information, evolu-
tionary information, and information from the GO (Gene
Ontology) database [18]. The default settings were used.
SNPs&GO classified each mutation variant as either “Neu-
tral” or “Disease” [15,18].
SIFT uses sequence homology from multiple sequence
alignments to predict the pathogenicity of a mutation
[14,15]. SIFT non-synonymous single nucleotide variants
(genome-scale) was used. The chromosomal location, gen-
omic coordinate, transcript orientation and base-pair
change of each SNVs were required for the SIFT nonsy-
nonymous single nucleotide variants (genome-scale) input
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(http://asia.ensembl.org/info/docs/tools/vep/index.html)
was used to generate the required information. The de-
fault settings were used for this study. SIFT classified each
variant as either “Tolerated” or “Damaging”.
The web-based PROVEAN Protein Batch Human was
used [16]. The PROVEAN algorithm classified each
SNV as either “Neutral” or “Deleterious”.
SNAP makes predictions based on protein secondary
structure, solvent accessibility and the conservation of
the amino acid of interest in a protein [19]. The default
settings were used. SNAP classified each mutation as
either “Neutral” or “Non-neutral” [19].
Meta-SNP [30] and PredictSNP [31] are metaservers
that combine the predicted outcomes from several in
silico tools to form a consensus prediction for a given
SNV. Meta-SNP uses a random forest approach to inte-
grate the predictions from in silico tools [30] (these are
listed in Table 1). Each mutation is classified as either
“Disease” or “Neutral” [30]. PredictSNP is a consensus
classifier that integrates the results from six in silico
prediction tools (listed in Table 1) as well as experi-
mental annotations from Protein Mutant Database and
UniProt [31].
The raw data output of all LQTS gene SNVs can be
found in the Additional file 3: Raw Data. The functional
predictions of all LQTS gene SNVs from all five in
silico tools and two metaservers were collated in Excel
spreadsheets. The location of each LQTS gene muta-
tion in the context of protein structure, as well as infor-
mation about whether the SNVs were functionally
characterised are shown in Additional file 1: Data tables
and Additional file 2: Figures S1–S3.
The data output were initially compared with the func-
tional studies’ results to determine the accuracy of the
programs. SNVs that were not functionally characterised
but were proven to be pathogenic through co-segregation
studies, or had an allelic frequency of greater than 1%,
were assumed to be pathogenic or benign, respectively.
These results were subcategorised into four groups: true
positives (TP, correct predictions for deleterious muta-
tions), true negatives (TN, correct predictions for neutral
mutations), false positives (FP, incorrect predictions for
neutral mutations) and false negatives (FN, incorrect pre-
dictions for deleterious mutations). The sensitivity (true
positive rate) and specificity (true negative rate) for each
in silico tool were determined using the four different
categories. Sensitivity was defined as the probability of
identifying true deleterious mutations, and this was calcu-
lated by [TP/(TP + FN)] x 100 [36]. Specificity was defined
as the probability of identifying true neutral mutations,
and this was calculated by [TN/(TN + FP)] x 100 [36]. The
Matthews Correlation Coefficient (MCC) was also calcu-
lated for each category using the following equation (TP xTN) – (FP x FN)/sqrt((TP + FP)(TP + FN)(TN+ FP)(TN +
FN)) [37]. The MCC measures how the predictions
correlate with the real target values, and the scores
range from +1 (always correct) to −1 (always false), and
0 represents a completely random prediction [36]. An
MCC score of more than 0.5 was considered acceptable
as this corresponds to more than 75% accuracy in bal-
anced data [38].
Receiver operating characteristic (ROC) curves and
the area under the ROC curve (AUC) [39] for each of
the single in silico tools and the two metaservers were
calculated using the pROC package in R [40]. ROC
curve plots sensitivity against 1-specificity, which depicts
the relative tradeoffs between the true positives and false
positives [39]. The probability scores of each in silico
prediction tool were used to calculate the curves and
AUC. An AUC of 1 represents a perfect prediction, an
AUC of 0.5 relates to predictions that are made by “pure
chance”, and an AUC less than 0.5 shows the predictions
are wrong.
The sensitivity percentage represents how well the in
silico tools and metaservers correctly predict pathogen-
icity, and the specificity percentage represents how well
they correctly predict non-pathogenic outcomes [36].
MCC, ROC curve and AUC were a more balanced over-
all evaluation of the ability of the prediction tools to cor-
rectly classify the SNVs compared to just analysing the
accuracy. ROC curves do not directly indicate the per-
formance of a method, but only shows the method’s
ranking potential for its overall performance [38].
The data output for each in silico tool were then ana-
lysed in combinations of two, three, four or all five in silico
tools, and the accuracy of the predictions, sensitivity, spe-
cificity and MCC were determined for each combination.
The conditions that an SNV must meet in order to be
categorised as “Tolerated” or “Damaging” in the case of
being assessed by two, three, four or all five in silico mis-
sense prediction tools are shown in Table 2. The AUC
scores were used as an indicator as to which in silico tools
performed best for a particular LQTS gene.
The differences between single tools and differing combi-
nations of tools in accuracy was calculated using the
Kruskal-Wallis test [41]. The best performing in silico tool/
combination of tools were chosen based on their MCC
scores, which is a more balanced approach to investigate
performance because it is less sensitive to different num-
bers of pathogenic and benign SNVs for each gene [36].
Results
A total of 312 missense SNVs (including pathogenic and
benign variants, see Table 3) in three LQTS genes were
analysed using five different in silico missense prediction
tools and two metaservers. To verify that the combined
in silico tools have different decision cutoffs, pairwise
Table 2 Conditions for SNV data output from two, three, four and all in silico missense prediction tools in order to be
considered tolerated and damaging
Number of in silico prediction tools SNV considered as Tolerated SNV considered as Damaging
Two tools Unanimous neutral/tolerated/benign Unanimous damaging/disease/deleterious/non-neutral
One output is damaging/disease/deleterious/non-neutral
Three tools Unanimous neutral/tolerated/benign Unanimous damaging/disease/deleterious/non-neutral
Two outputs are neutral/tolerated/benign Two outputs are damaging/disease/deleterious/non-neutral
Four tools Unanimous neutral/tolerated/benign Unanimous damaging/disease/deleterious/non-neutral
Three outputs are neutral/tolerate/benign Two or more outputs are damaging/disease/deleterious/
non-neutral
All tools Unanimous neutral/tolerated/benign Unanimous damaging/disease/deleterious/non-neutral
Three outputs are neutral/tolerated/benign Three or more outputs are damaging/disease/deleterious/
non-neutral
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lated to ensure no strong correlation between any pair
of tools would affect the combined results (Additional
file 4: Tables S1–S4). ROC curves were calculated for
each individual in silico prediction tools and metaservers
(Table 4), and the possible outcomes for the five in silico
tools and metaservers are shown in Figures 1 and 2.
KCNQ1
The ROC curves of the individual in silico prediction tools
and metaservers showed that Meta-SNP, PROVEAN,
SNPs&GO and SIFT were the best tools for KCNQ1 gene
predictions (Figure 3). The AUC scores showed that
Meta-SNP, PROVEAN, PolyPhen-2 and SNPs&GO were
the best tools (Table 4), while MCC scores ranked SIFT,
Meta-SNP, PolyPhen-2, PROVEAN and PredictSNP as the
best tools (Figure 1) for KCNQ1 gene predictions.
There were no significant differences between the accur-
acy of the different combinations of in silico tools and the
metaservers alone. However, based on the MCC scores,
the best combination of in silico tools for KCNQ1 was
PROVEAN, SNPs&GO and SIFT (MCC score of 0.70;
Figure 1). This combination had an accuracy of 92.7%,
sensitivity of 93.1% and specificity of 100% (Figure 1).
Despite not having the highest accuracy (94.5% achieved
by SNAP and SNPs&GO), the combination of PROVEAN,
SNPs&GO and SIFT was able to correctly classify both
pathogenic and benign SNVs equally well (Figure 1).
When all five in silico tools were used, the combinedTable 3 The total number of functionally characterised
KCNQ1, KCNH2 and SCN5A gene variants investigated in
this study
Gene Pathogenic Benign Total
KCNQ1 101 8 109
KCNH2 82 8 90
SCN5A 99 14 113
Total 312results were almost as good with an MCC score of 0.69
(Figure 1). The two combinations of tools also surpassed
the performance of both metaservers in terms of accuracy,
sensitivity and MCC scores.
KCNH2
According to the ROC curves, PROVEAN, Meta-SNP,
SIFT and SNPs&GO were the best tools (Figure 3), and
the AUC scores ranked Meta-SNP, PROVEAN, SNPs&GO
and SIFT as the best tools for KCNH2 gene predictions
(Table 4). PROVEAN, Meta-SNP and SIFT had the high-
est MCC scores (Figure 1).
Like KCNQ1, there were no significant differences in the
accuracy of the different combinations of in silico tools
and the metaservers alone. Based on the MCC scores,
SIFT and PROVEAN, and PROVEAN, SNPs&GO and
SIFT were the best combinations for KCNH2 gene predic-
tions (Figure 1). Both combinations had an accuracy of
91.1%, with sensitivity of 91.5%, specificity of 87.5%, and
an MCC score of 0.62 (Figure 1). PROVEAN-alone;
PolyPhen-2, SIFT and PROVEAN and SIFT, PROVEAN
and SNAP were almost as good (MCC of 0.57; Figure 1).
The two metaservers did not perform as well compared to
the two best combinations of in silico tools.
SCN5A
SNVs in the SCN5A gene cause either LQTS and/or Bru-
gada syndrome (BrS) and the analysis was performed on
the group of SNVs without separating them by phenotype.
The combination of in silico tools with the best perform-
ance, based on the MCC scores, remains the same for the
SCN5A gene regardless of whether BrS variants were in-
cluded or not (Additional file 4). No single predictive tool
appeared to work well for the SCN5A gene (Figure 3), and
the AUC scores ranked SNPs&GO, SIFT, Meta-SNP and
PolyPhen-2 as the best programs (Table 4); however, the
scores suggested that the chances of the correct prediction
being made was a little better than “pure chance”. This
was also reflected by the MCC scores (Figure 1).
Table 4 Area under the curve (AUC) calculated from Receiver operating curves for each of the in silico prediction tools
alone using their respective probabilities/scores for KCNQ1, KCNH2, SCN5A and all genes combined
Programs KCNQ1 KCNH2 SCN5A All genes
AUC CI AUC CI AUC CI AUC CI
PolyPhen-2 0.942 (0.877-1.000) 0.774 (0.624-0.924) 0.626 (0.485-0.767) 0.769 (0.688-0.850)
SNPs&GO 0.933 (0.882-0.984) 0.864 (0.752-0.976) 0.666 (0.528-0.803) 0.781 (0.714-0.849)
SIFT 0.834 (0.687-0.982) 0.819 (0.729-0.910) 0.643 (0.450-0.836) 0.715 (0.602-0.828)
PROVEAN 0.943 (0.891-0.995) 0.904 (0.840-0.968) 0.631 (0.456-0.807) 0.786 (0.689-0.883)
SNAP 0.689 (0.500-0.877) 0.397 (0.194-0.600) 0.590 (0.421-0.758) 0.627 (0.522-0.732)
Meta-SNP 0.959 (0.918-0.999) 0.905 (0.826-0.984) 0.639 (0.506-0.772) 0.839 (0.781-0.897)
PredictSNP 0.713 (0.571-0.856) 0.549 (0.373-0.725) 0.555 (0.397-0.714) 0.603 (0.513-0.693)
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as well for the SCN5A gene as for KCNQ1 and KCNH2
genes (Figure 1). There were no significant differences
between the different combination of in silico tools re-
garding accuracy. The overall MCC scores were low,
with SNAP and PROVEAN giving the highest score of
0.32. For this combination, the accuracy was 81.4%, with
sensitivity of 86.9% and specificity of 50.0% (Figure 1).
Both metaservers performed poorly.
Due to the poor performance of the in silico tools on
SNVs in the SCN5A gene as a whole, the analysis of the
SNVs was separated into two groups: those that lay in the
amino-/carboxyl-terminus and all transmembrane do-
mains, and those that lay in all the loop regions of SCN5A.
The MCC scores for all in silico tools and metaservers
tested improved when only the amino-/carboxyl-terminus
and all transmembrane domains were considered; how-
ever, the scores were still very low compared to both the
KCNQ1 and KCNH2 gene results (Figure 2). The combin-
ation with the best performance for the amino-/carboxyl-
terminus and all transmembrane domains of SCN5A was
SIFT and PROVEAN (MCC score 0.36; Figure 2). The
analysis of variants in the loop regions was very poor, with
MCC scores ranging from −0.50 – 0.35 (Figure 2). SNAP
and PROVEAN is the best in silico tool combination for
analysing SNVs in the SCN5A loop regions (MCC score
0.35; Figure 2). Both metaservers performed poorly for
these regions (Figure 2). As these results are comparable
to the analysis of SCN5A as a whole, it was decided that
the combination of tools with the best performance will
be based on that analysis.
All genes
According to the ROC curves SIFT, Meta-SNP, SNPs&GO
and PolyPhen-2 were the top four single programs when all
three LQTS genes’ SNVs were combined (Figure 3). The
AUC scores ranked Meta-SNP, PROVEAN, SNPs&GO and
PolyPhen-2 as the best tools for all gene predictions
(Table 4). The MCC scores ranked SIFT, PROVEAN,
Meta-SNP and PredictSNP as the best tools (Figure 1).There were no significant differences between the ac-
curacy of the different combinations of in silico tools.
Based on MCC scores the combination of in silico tools
with the best performance was SIFT, PROVEAN and
SNAP (Figures 1 and 3). This combination had an accur-
acy of 82.7%, with sensitivity of 83.0%, specificity of
80.0% and MCC of 0.44 (Figure 1). SIFT and PROVEAN,
as well as PolyPhen-2, SIFT and PROVEAN, and PRO-
VEAN, SNPs&GO and SIFT, performed almost as well
(MCC score 0.43; Figure 1). These three combinations
of in silico tools had higher accuracy and sensitivity but
lower specificity compared to SIFT, PROVEAN and SNAP
(Figure 1). The metaservers did not perform as well as the
combination of in silico tools with the best performance in
terms of accuracy and sensitivity (Figure 1).
Discussion
The current study investigated the combination of in
silico prediction tools with the best performance for
LQT 1–3 genes. The analysis was restricted to mutations
in these genes as they account for approximately 70%-
75% of congenital LQTS cases, and the remaining genes
only make up ~5% of cases [42]. For the minor genes,
very few SNVs (both pathogenic and benign) fit the
strict criteria set for the current study and therefore
these genes were not analysed. In the case of SCN5A,
both LQTS and BrS SNVs were analysed together. This
was done as the distinction between both LQT3 and
Brugada syndrome is not clear cut as some mutations in
the SCN5A gene are associated with both diseases [43-46];
however, the combination of in silico tools with the best
performance remained the same regardless of whether the
LQTS and BrS mutations were separated or not.
PolyPhen-2, SIFT, PROVEAN and SNPs&GO were
chosen as they are routinely used in the author’s diagnos-
tic laboratory. Both PolyPhen-2 and SIFT are the most
common prediction tools used in diagnostic laboratories.
SNAP was chosen as another supervised-learning based
tool that incorporates a wider range of features (evolution-
ary information, structural features and protein annotation
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PolyPhen-2 91.8 95.0 62.5 0.52 80.0 82.9 50.0 0.23 70.8 78.8 21.4 0.00 81.4 85.8
SNPs&GO 93.6 99.0 37.5 0.51 87.8 93.9 25.0 0.20 70.8 78.8 21.4 0.00 84.3 90.4
SIFT 90.9 91.1 100.0 0.65 82.2 81.7 87.5 0.46 68.1 71.7 50.0 0.15 81.1 81.6
PROVEAN 87.3 88.1 87.5 0.52 88.9 89.0 87.5 0.57 69.9 72.7 57.1 0.21 82.1 83.0
SNAP 80.9 88.1 0.0 -0.10 82.2 85.4 50.0 0.26 76.1 80.8 50.0 0.24 80.1 84.8
SIFT & PolyPhen-2 92.7 96.0 62.5 0.55 88.9 92.7 50.0 0.39 75.2 84.8 14.3 -0.01 85.9 91.1
SIFT & PROVEAN 91.8 93.1 87.5 0.63 91.1 91.5 87.5 0.62 74.3 79.8 42.9 0.12 85.9 87.9
SIFT & SNPs&GO 93.6 99.0 37.5 0.51 90.0 96.3 25.0 0.27 75.2 84.8 14.3 -0.01 86.5 93.3
PolyPhen-2 & 
PROVEAN
92.7 96.0 62.5 0.55 88.9 92.7 50.0 0.39 75.2 83.8 21.4 0.05 85.9 90.8
PolyPhen-2 & 
SNPs&GO
92.7 99.0 25.0 0.38 91.1 97.6 25.0 0.31 79.6 88.9 21.4 0.10 88.1 95.0
PROVEAN & 
SNPs&GO
92.7 99.0 25.0 0.38 90.0 96.3 25.0 0.27 74.3 82.8 21.4 0.04 85.9 92.6
PolyPhen-2 & SNAP 90.9 96.0 37.5 0.36 87.8 92.7 37.5 0.29 81.4 90.9 21.4 0.13 87.2 93.3
SIFT & SNAP 92.7 96.0 62.5 0.55 85.6 89.0 50.0 0.32 78.8 85.9 35.7 0.20 86.2 90.4
SNAP & PROVEAN 89.1 93.1 50.0 0.37 88.9 91.5 62.5 0.45 81.4 86.9 50.0 0.32 86.9 90.4
SNAP & SNPs&GO 94.5 100.0 37.5 0.60 90.0 96.3 25.0 0.27 81.4 90.9 21.4 0.13 89.1 95.7
PolyPhen-2, SIFT & 
PROVEAN
91.8 93.1 87.5 0.63 88.9 89.0 87.5 0.57 73.5 78.8 42.9 0.17 85.3 86.9
PolyPhen-2, SIFT & 
SNPs&GO
93.6 96.0 75.0 0.64 87.8 91.5 50.0 0.36 70.8 78.8 21.4 0.00 84.3 88.7
PROVEAN,
SNPs&GO & SIFT
92.7 93.1 100.0 0.70 91.1 91.5 87.5 0.62 67.3 71.7 42.9 0.10 84.0 85.1
PolyPhen-2, PROVE-
AN & SNPs&GO
92.7 96.0 62.5 0.55 87.8 91.5 50.0 0.36 69.9 77.8 21.4 -0.01 83.7 88.3
PolyPhen-2, SNAP & 
SIFT
92.7 94.1 87.5 0.66 84.4 86.6 62.5 0.37 73.5 78.8 42.9 0.16 83.7 86.2
PolyPhen-2, SNAP & 
PROVEAN
89.1 91.1 75.0 0.50 86.7 89.0 62.5 0.40 72.6 79.8 28.6 0.07 83.0 86.5
PolyPhen-2, SNAP & 
SNPs&GO
90.9 95.0 50.0 0.43 86.7 91.5 37.5 0.26 74.3 82.8 21.4 0.04 84.3 89.7
SIFT, PROVEAN & 
SNAP
90.0 90.1 100.0 0.63 88.9 89.0 87.5 0.57 69.0 70.7 64.3 0.24 82.7 83.0
SIFT, SNAP & 
SNPs&GO
91.8 95.0 62.5 0.52 85.6 89.0 50.0 0.32 69.9 74.7 42.9 0.13 82.4 85.8
PROVEAN,
SNPs&GO & SNAP
89.1 92.1 62.5 0.44 87.8 91.5 50.0 0.36 69.9 76.8 28.6 0.04 82.4 86.5
PolyPhen-2, PROVE-
AN, SNPs&GO & 
SIFT
92.7 96.0 62.5 0.55 88.9 92.7 50.0 0.39 73.5 81.8 21.4 0.03 85.3 90.1
PolyPhen-2, SIFT, 
PROVEAN & SNAP
92.7 95.0 75.0 0.61 88.9 91.5 62.5 0.45 71.7 82.8 0.0 -0.16 84.6 89.7
PolyPhen-2, SIFT, 
SNPs&GO & SNAP
91.8 96.0 50.0 0.46 87.8 92.7 37.5 0.29 73.5 84.8 0.0 -0.15 84.6 91.1
PolyPhen-2, PROVE-
AN, SNPs&GO & 
SNAP
90.9 96.0 37.5 0.36 87.8 92.7 37.5 0.29 72.6 83.8 0.0 -0.15 84.0 90.8
SIFT, PROVEAN,
SNPs&GO & SNAP
91.8 95.0 62.5 0.52 87.8 91.5 50.0 0.36 69.0 79.8 0.0 -0.17 83.0 88.7
All Five in silico 
Tools
93.6 95.0 87.5 0.69 86.7 89.0 62.5 0.40 66.4 76.8 0.0 -0.19 82.4 86.9
Meta-SNP 85.5 85.1 100.0 0.54 84.4 84.1 87.5 0.49 54.0 53.5 64.3 0.12 74.4 73.8
PredictSNP 83.6 83.2 100.0 0.52 82.2 82.9 75.0 0.40 59.3 60.6 57.1 0.12 75.0 75.2
Figure 1 The accuracy (acc), sensitivity (sens), specificity (spec) and MCC scores of all the different combinations of in silico prediction tools
and metaservers for variants in the KCNQ1, KCNH2, SCN5A genes, and all genes combined. The sensitivity and specificity percentages
highlighted in light green represent the combination of in silico tools and metaservers with high sensitivity or specificity percentages; dark
green represents the combination of in silico tools or metaservers with the best performance; light blue represents the combination of in
silico tools and metaservers with high MCC scores, and dark blue represents the combination of in silico tools or metaservers with the best
performance; light orange represents the combination of in silico tools and metaservers with high accuracy percentages; yellow represents
the combination of in silico tools or metaservers with the best performance; red represents the combination of in silico tools and metaservers
with MCC scores below 0.
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rithm than SNPs&GO. Both metaservers (Meta-SNP and
PredictSNP) were chosen as they incorporate the results
from a good selection of in silico prediction tools that span
different types of methods.
The approach that was used to categorise variants as
“pathogenic” or “benign” based on combined results fromthe five in silico prediction tools as shown in Table 2. This
approach was taken to ensure that all likely pathogenic
SNVs would not be missed and that benign SNVs were
correctly called. “Over-calling” pathogenic SNVs may
occur when an even number of in silico tools are used as
the conditions set out for this study “call” an SNV with
equal numbers of “pathogenic” and “benign” results as
Figure 2 The accuracy (acc), sensitivity (sens), specificity (spec) and MCC scores of all the different combinations of in silico prediction tools
and metaservers for the whole of SCN5A, only the amino-/carboxyl-terminus and transmembrane domain (N/TM/C) of SCN5A, and only the
loop regions of SCN5A. The sensitivity and specificity percentages highlighted in light green represent the combination of in silico tools and
metaservers with high sensitivity or specificity percentages; dark green represents the combination of in silico tools or metaservers with the
best performance; light blue represents the combination of in silico tools and metaservers with high MCC scores, and dark blue represents the
combination of in silico tools or metaservers with the best performance; light orange represents the combination of in silico tools and meta-
servers with high accuracy percentages; yellow represents the combination of in silico tools or metaservers with the best performance; red
represents the combination of in silico tools and metaservers with MCC scores below 0.
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Figure 3 Receiver operating characteristic (ROC) curves for KCNQ1, KCNH2, SCN5A and all genes combined for each of the single in silico
prediction tools and the two metaservers.
Leong et al. BMC Medical Genetics  (2015) 16:34 Page 9 of 13“pathogenic”. For KCNQ1, 4%-15% of SNVs; KCNH2,
5%-21% of SNVs; and SCN5A, 8%-24% of SNVs fall into
this category. However, these conditions ensured that
the classification of “benign” SNVs is more stringent,
and so would minimise the chance of a possible patho-
genic SNVs being classified as “benign” and therefore
dismissed.
In silico tools that correctly predict pathogenic vari-
ants do not necessarily perform well for benign predic-
tions. The combinations that were chosen for all three
genes were based on how well the prediction tools were
able to identify both pathogenic and benign SNVs,
thereby reducing the number of false positive and false
negative calls. The tools chosen for each gene do not ne-
cessarily yield the highest accuracy. In the clinical setting
it may in fact be preferable to use an in silico tool whichis likely to under-call the likelihood of malignancy in
favour of improved specificity. This will mean that in a
family cascade, fewer people will be erroneously labelled
as having the disease on the basis of a genetic test result.
In the case of calling a truly pathogenic variant as be-
nign, the clinician must use clinical evaluation of family
members in order to reveal the truth in a segregation
study. In the current study, the optimal number of in
silico tools for KNCQ1, KCNH2, and when all genes are
considered together, is three. Only SCN5A requires two
in silico tools to make the best predictions. Therefore,
the “over-calling” issue should be minimised.
The current study also highlights the need to systemat-
ically test which combinations of in silico tools perform
the best for a given gene, and not assume that a large
number of programs will provide the best prediction
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agree frequently due to the different algorithms they are
based on [21,23]. When considering the predictions for
pathogenic KCNQ1 SNVs by all five in silico tools, 82
SNVs (81%) had concordant results; however, when only
considering KCNQ1’s combination of tools with the
best performance (PROVEAN, SNPs&GO and SIFT),
an additional six SNVs were agreed upon (88 SNVs,
88%; Additional file 2). In the case of benign KCNQ1
SNVs, there were no improvements when considering
only the results of the tools with the best performance
compared to considering all five tools (two SNVs, 25%;
Additional file 2). All five tools agreed for 58 KCNH2
pathogenic SNVs (71%), and this increased to 68 SNVs
(83%) when only considering the results from the com-
bination of tools with the best performance. There were
three benign SNVs (37.5%) that had the same predic-
tions for all five tools and this increased by one SNV
(4, 50%; Additional file 2) when considering the tools
with the best performance. In the case of pathogenic
SCN5A gene mutations, 61 SNVs (62%) had the same
predictions for all five in silico tools and this increased
to 79 SNVs (80%) when only considering PROVEAN
and SNAP (Additional file 2). Five benign SCN5A SNVs
(36%) had the same predictions for all five tools and
this increased by two SNVs (7, 50%) when only consid-
ering PROVEAN and SNAP (Additional file 2). When
considering the predictions for all pathogenic SNVs,
201 SNVs (71%) had the same predictions for all five in
silico tools; however, when considering the results from
PROVEAN, SIFT and SNAP, this increased by 26 SNVs
(227, 81%; Additional file 2). For all benign mutations,
only 10 SNVs (33%) had the same predictions from all
five tools, and this increased by four SNVs (14, 47%)
when only PROVEAN, SIFT and SNAP were consid-
ered (Additional file 2).
Both KCNQ1 and KCNH2 encode for cardiac potas-
sium channels and the structure of these two proteins
are very similar. This could be the reason why the com-
bination of in silico prediction tools with the best per-
formance are the same for these two genes (PROVEAN,
SNPs&GO and SIFT), with KCNH2 having SIFT and
PROVEAN as an additional combination. The reason for
both SIFT and PROVEAN working well together could
be because they belong to the sequence and evolutionary
conservation-based evaluation method, which relies solely
on evolutionary sequence conservation information and
does not take into account protein structural information
(unlike PolyPhen-2) [14-16]. Studies conducted by Chan
et al. [20] showed that methods based on evolutionary se-
quence conservation had high predictive values regardless
of whether protein information is used. The addition of
SNPs&GO to SIFT and PROVEAN could be because
SNPs&GO uses evolutionary derived information [18],which is similar to SIFT and PROVEAN, and the inclusion
of the information from the Gene Ontology database
makes this combination best suited for the KCNQ1 and
KCNH2 genes.
No prediction tools are considered suitable for analysing
variants in the SCN5A gene from this study. The results
for tools that incorporate protein structure and function
into their algorithms (PolyPhen-2, SNPs&GO and SNAP)
had low specificity suggesting that functional and struc-
tural information hampered predictions for variants in the
SCN5A gene. This may be due to the two different SCN5A
isoforms present in the normal human heart. The isoforms
differ by only one amino acid (NP_000326 has glutamine-
1077 deleted compared to NP_932173) [48]. The transcript
encoding for NP_000326 represents 65% of the SCN5A
gene in the normal heart [48], and depending on which
isoform the SNV is present in, the effect of the mutation
may differ [49]. A study investigating the functional charac-
teristics of eight common SCN5A gene polymorphisms
found five of the eight polymorphisms were similar to the
unaffected SCN5A protein in the NP_000326 isoform, and
only three of the eight were similar to the unaffected
SCN5A protein in the NP_932173 isoform [49]. The poly-
morphisms that affected the function of the SCN5A
protein, regardless of which isoform they were present in,
affected the protein in different ways [49]. These results
could account for the large number of polymorphisms
characterised as damaging in this study (14 of 18 polymor-
phisms were classified as damaging; Additional file 1: Data
Tables); of relevance here is the need to specify the protein
isoform in some of the in silico programs.
Another confounding factor in the in silico analysis may
lie in the fact that some SCN5A SNVs can cause both
LQTS and BrS. Gain-of-function mutations are associated
with BrS and loss-of-function mutations are associated
with LQTS [50]. Flanagan et al., found that both SIFT and
PolyPhen-2 had more success predicting loss-of-function
compared to gain-of-function mutations [22] and this
could also be the case with the other three in silico tools
used here, hence the low MCC and AUC scores.
The protein context (isoform) of SNVs in SCN5A
highlights an important issue when reporting results for
diagnostic tests using in silico prediction tools. These
tools make predictions based only on amino acid se-
quence and protein structure information, and very little
information about protein function. Caution should be
used when making clinical diagnosis based solely on
predictive results. As demonstrated by the two isoforms
of SCN5A, a single amino acid difference can have a
significant effect in terms of protein function and inter-
actions between the ion channels and their accessory
proteins. The ideal prediction tool should incorporate
information of not just the amino acid sequence and
protein structure, but also the protein’s function and
Figure 4 Procedure used for assessing new missense mutations using in silico prediction tools for KCNQ1, KCNH2 and SCN5A. The in silico
prediction tools for SCN5A are italicised as SNAP & PROVEAN should be used with caution for the prediction of SCN5A SNVs.
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aspects are included in the SNPs&GO and SNAP pro-
grams, more research is required to resolve protein func-
tion and interactions in order for these to be incorporated
into prediction tools. Therefore, in silico predictions
should act as an indicator of whether a variant of un-
known significance is pathogenic or benign, and if func-
tional studies are available, clinical information should be
used to characterise the variant.
Compared to the different combinations of in silico
tools, the metaservers were not significantly better despite
their claims of improved performance over individual inte-
grated tools [30,31]. Both Meta-SNP’s and PredictSNP’s
performance were comparable to many of the different
combinations of in silico prediction tools, with Meta-SNP
performing slightly better. The metaservers performed
better than individual in silico tools; however, compared to
the combination of tools with the best performance the
metaservers’ accuracy, sensitivity and MCC scores were
not as good. Despite this the metaservers had high specifi-
city compared to some of the in silico tools.
A major limitation of this study is the low number of
benign SNVs for all three LQTS genes. Attempts to ad-
dress this deficiency by including polymorphisms that
have not been functionally characterised only led to a
marginal increase in benign SNVs. Therefore, the ana-
lysis of the ability of the in silico tools to correctly pre-
dict an SNV to be benign may not be as reliable as the
analysis of the tools’ ability to correctly predict an SNV
to be pathogenic.
Another limitation is that in the current study only
SIFT, PolyPhen-2, PROVEAN, SNPs&GO, SNAP, Meta-
SNP and PredictSNP were investigated in the prediction
of SNVs for LQT 1–3 genes; however, it is not to say that
these are the only programs that are effective for these
genes. For both KCNQ1 and KCNH2, sequence and evolu-
tionary conservation-based in silico prediction tools ap-
pear to work best as demonstrated by the success of
PROVEAN, SIFT and SNPs&GO. The results for SCN5A
and an overall combination of in silico tools for all three
genes did not appear promising. However, for SCN5A a
combination of sequence and evolutionary conservation-based method with a supervised-learning method that
uses a wide-spread method may be the best choice. In this
study, SNAP appeared to work better than the other
five in silico tools in analysing SCN5A gene variants.
SNAP is a supervised-learning method using neural
networks to make predictions, and it incorporates evo-
lutionary constraints, structural features and protein
annotation information [19].Conclusions
The reliance on in silico prediction tools to make a diag-
nosis is high in light of the inability to functionally charac-
terise each LQTS mutation that is discovered in diagnostic
laboratories. This study confirms that these tools must
never be relied on as the final arbiter of pathogenicity.
Rather, a result should be seen as raising or lowering prob-
ability. This study shows that the level of confidence in the
result and the combinations of prediction tools with the
best performance are gene-dependent, and metaservers,
while better than the single in silico prediction tools, did
not perform better than the combinations of in silico tools
with the best performance for each of the LQTS genes in-
vestigated. The assessment of variants in the SCN5A gene
is significantly less reliable than those in the KCNQ1 or
KCNH2 genes, and should be used with caution. Figure 4
summarises the in silico tools with the best performance
for all three genes.
Wherever possible, clinical family-based co-segregation
studies centred around clinical registries, and supported
with in vitro evidence, should form the basis of an assign-
ment of pathogenicity [3,7]. Careful genetic counselling
should convey the probabilistic nature of genetic testing
both to the patient and their attending clinicians.Additional files
Additional file 1: Data tables for all the mutations for KCNQ1,
KCNH2 and SCN5A genes that were analysed and their respective
results.
Additional file 2: Figure legends for all five supplementary figures.
The zipped file contains all supplementary figures in eps format.
Leong et al. BMC Medical Genetics  (2015) 16:34 Page 12 of 13Additional file 3: Raw data. The zipped file contains all raw data results
in txt format from the five different in silico prediction tools and two
metaservers.
Additional file 4: Tables S1-S4. Data tables of the pairwise correlation
of in silico prediction tools for KCNQ1, KCNH2 and SCN5A genes, and all
three genes.
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